golden diabet dash today
pipelin tomorrow upgrad buy pt
put stellar report upbeat commentari dash
underli factor push patient demand higher didnt
perfectli time recent bottom share slid bit think time
right upgrad given numer growth driver anticip
next sever qtr greater access via pharmaci high patient
interest dash no-commit pay model cover live new
ou area beyond two shot goal autom insulin
deliveri horizon loop across diabet tech landscap
seem new entrant improv capabl spur patient
eager product see somewhat protect
competit price concern carv nich
patch pump welcom near-term revenu loss elimin
exchang flexibl higher patient add think
still earli day strong expans would buy share
beat guidanc rais dash
demand even better expect appeal pay-as-you-
go becom appar think may keep exceed
expect review result model chang
competit buy pt
see omnipod easy-to-us dispos offer appeal
mdi patient littl nois roch rhhbi
rate tubeless accu-chek solo pump sinc ce mark
pump expect eventu includ becton dickinson
rate swatchslat limit launch throughout late
devic rate reportedli
develop part autom insulin deliveri system horizon
loop help stay front tech advanc
valuat pt base mo revenue estim
risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
exceed sale forecast first quarter
omnipod revenu higher forecast
intern omnipod sale bit estim
drug deliveri revenu came estim
gross margin bp higher model sg spend well
control come bp estim mostli off-set
 spend bp forecast strong revenu result healthi
gross margin rel in-lin oper spend ad ep beat
actualsbtig estimate varianceu omnipod omnipod deliveri spend spend spend oper btig estim compani filingsvari
revis revenu outlook account compani guidanc
reduc ou omnipod revenu estim get closer
guidanc rang forecast remain top end rang
divis leav drug deliveri revenu forecast unchang
rest leav drug deliveri omnipod sale
estim unchang trim ou omnipod revenu remain almost
top end guidanc rang believ focu
direct busi model europ continu drive strong result
adjust result updat total revenu estim
chang outyear omnipod revenu
estim increas ou revenu estim come slightli drug
deliveri sale outlook unchang overal total revenu estim
increas
make mani chang forecast sinc remain target
guidanc manag commentari increas gross
margin bit leav alon reflect commentari
manufactur ramp leav metric unchang outyear also
keep oper spend estim model non-gaap ep
insulet rate buy pt base month
revenu forecast share trade approxim multipl
ntm revenu estim believ multipl line fast-
grow med-tech comp group deserv podd robust revenu
ramp grow patient awar diabet technolog favor shift
payor pharmaci channel dynam product pipelin risk
rate includ disrupt intern revenu instal patient
base increas competit potenti prefer partnership
major insur group lack visibl next drug deliveri
product
bpsebit bpssourc btig estim compani filingsnewold chang
ntm inc ingnnot diabetestndmnot medicalwmginot factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap
incom statement adjust nd etot revenu y/i growth adjust neighborhood good oper expens tax expens net incom share net incom adjustments- gaap net incom gaap ep growth y/ymarginsgross incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnet incomenmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmexpensescog oper expens quarterli result growth rate adjust neighborhood divestituresourc btig estim compani report
revenu etot revenu omnipod y/i omnipod y/i deliveri y/i revenu exclud neighborhood y/i growth adjust neighborhood revenu omnipod revenu breakdownbegin instal new patient start patient y/i patient attrit instal instal base average es order per re-ord annual new user quarterli annual asp new patient revenu new user total omnipod y/i productivity/rep omnipod revenu breakdownbegin instal new patient patient y/i patient attrit instal instal base average es order per re-ord quarterli annual asp new user quarterli annual asp new patient new user total omnipod y/i deliveri revenuesymphoni health data forecast neulasta syring neulsasta onpro total neulasta y/i estim neulasta sale attribut onpro neulasta sale attribut onpro deliverynmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnmnm total neulasta onpro end-us neulasta onpro impli neulasta onpro total neulasta onpro total neulasta onpro revenu total neulasta onpro drug total report drug deliveri sourc btig estim compani report symphoni health solut symphoni health symphoni health b/c btig estim report drug deliveri revenu /f btig estim
btig cover compani mention report
appendix analyst certif import disclosur
